 |
|
|
| |
Evaluation of Renal and Bone Safety at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
|
| |
| |
EASL 2022 June 22-26 London
Edward J. Gane,1 Rica Dagooc,1 Dominic Ray-Chaudhuri,1 Thomas Mules,1 Frida Abramov,2 Curtis D. Holt,2 Hongyuan Wang,2 Vithika Suri,2 Anu O. Osinusi,2 John F. Flaherty2
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
